Steroid-dependent polyarthritis induced by immune checkpoint inhibitor therapy successfully treated with bimekizumab

Immune checkpoint inhibitors (ICIs) are an integral part of modern-day cancer therapy. Along with a greatly improved antitumor response come a number of immune-related adverse events (irAEs), musculoskeletal irAEs rank among the less frequent manifestations. The mechanisms behind these events are po...

Full description

Saved in:
Bibliographic Details
Published inImmunotherapy Vol. 16; no. 5; p. 287
Main Authors Springer, Robin, Lange, Kristin, Homey, Bernhard, Meller, Stephan, Lindhof, Harm-Henning
Format Journal Article
LanguageEnglish
Published England 01.03.2024
Subjects
antibody therapeutics
dermatology
arthritis
IL-17
cancer immunology
immune-related adverse events
bimekizumab
checkpoint inhibitors
Online AccessGet more information

Cover

More Information
Summary:Immune checkpoint inhibitors (ICIs) are an integral part of modern-day cancer therapy. Along with a greatly improved antitumor response come a number of immune-related adverse events (irAEs), musculoskeletal irAEs rank among the less frequent manifestations. The mechanisms behind these events are poorly understood, and so far clear guidelines for therapeutic management beyond treatment with glucocorticosteroids are lacking. We present the case of a 72-year-old patient who developed a severe ICI-induced polyarthritis that could not be controlled by glucocorticosteroids. We initiated an immunomodulating therapy with the IL-17A/F/AF-inhibitor bimekizumab, which lead to a full clinical and sonographic remission.
ISSN:1750-7448
DOI:10.2217/imt-2023-0252